Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Docosanol→

Docosanol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
661-19-8
Molecular formula
C22H46O
Molecular weight
326.6 g/mol
Drug class
Long-chain saturated fatty alcoholtopical antiviral entry inhibitor
Mechanism of action
Interferes with fusion between the viral envelope and host-cell plasma membrane, preventing entry of herpes simplex virus into cells. It does not inactivate established intracellular viral replication.
Indications / reported uses
  • Topical treatment of recurrent herpes labialis (cold sores) in adults and adolescents aged 12 years and older, with initiation at the earliest prodromal symptom under the US product indication

Sources: US DailyMed — ABREVA (docosanol) · US FDA OTC label — Docosanol 10% cream · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Docosanol Environmental Risk Assessment (ERA) (the Docosanol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.